Karthik K Karunakar , Binoy Varghese Cheriyan , Dheena Babu , Devan P , Nandhini J , Suresh Kannan M , Lincy Yabase , Kunal Kataria
{"title":"Selenium, silver, and gold nanoparticles: Emerging strategies for hepatic oxidative stress and inflammation reduction","authors":"Karthik K Karunakar , Binoy Varghese Cheriyan , Dheena Babu , Devan P , Nandhini J , Suresh Kannan M , Lincy Yabase , Kunal Kataria","doi":"10.1016/j.ntm.2025.100085","DOIUrl":null,"url":null,"abstract":"<div><div>Liver failure, primarily driven by oxidative stress and inflammation, remains a significant clinical challenge. Conventional hepatoprotective strategies often fail to provide effective long-term protection, necessitating the exploration of novel therapeutic approaches. This review focuses on the hepatoprotective potential of selenium (SeNPs), silver (AgNPs), and gold nanoparticles (AuNPs), emphasizing their antioxidant, anti-inflammatory, and immunomodulatory mechanisms. SeNPs enhance antioxidant defenses by scavenging reactive oxygen species (ROS) and upregulating key enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx). AgNPs exhibit anti-inflammatory effects by modulating cytokine expression, reducing lipid peroxidation, and preserving hepatic architecture. AuNPs demonstrate biocompatibility, fibrosis prevention, and immune modulation through NF-κB and Nrf2 signaling. Despite their therapeutic promise, concerns regarding nanoparticle biocompatibility, stability, and potential toxicity remain key challenges for clinical translation. This review aims to explore the role of (SeNPs), (AgNPs), and (AuNPs) in mitigating oxidative stress and inflammation in liver diseases, explore their mechanisms of hepatoprotection, assess the challenges associated with their biomedical applications, and provide insights into future directions for their clinical development. Addressing these gaps will be crucial in optimizing nanoparticle-based hepatoprotective therapies for safer and more effective liver disease management.</div></div>","PeriodicalId":100941,"journal":{"name":"Nano TransMed","volume":"4 ","pages":"Article 100085"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nano TransMed","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2790676025000160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Liver failure, primarily driven by oxidative stress and inflammation, remains a significant clinical challenge. Conventional hepatoprotective strategies often fail to provide effective long-term protection, necessitating the exploration of novel therapeutic approaches. This review focuses on the hepatoprotective potential of selenium (SeNPs), silver (AgNPs), and gold nanoparticles (AuNPs), emphasizing their antioxidant, anti-inflammatory, and immunomodulatory mechanisms. SeNPs enhance antioxidant defenses by scavenging reactive oxygen species (ROS) and upregulating key enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx). AgNPs exhibit anti-inflammatory effects by modulating cytokine expression, reducing lipid peroxidation, and preserving hepatic architecture. AuNPs demonstrate biocompatibility, fibrosis prevention, and immune modulation through NF-κB and Nrf2 signaling. Despite their therapeutic promise, concerns regarding nanoparticle biocompatibility, stability, and potential toxicity remain key challenges for clinical translation. This review aims to explore the role of (SeNPs), (AgNPs), and (AuNPs) in mitigating oxidative stress and inflammation in liver diseases, explore their mechanisms of hepatoprotection, assess the challenges associated with their biomedical applications, and provide insights into future directions for their clinical development. Addressing these gaps will be crucial in optimizing nanoparticle-based hepatoprotective therapies for safer and more effective liver disease management.